CD274 and neoplasm: Thus blocking PD-L1/PD-1 avoids systemic overreactions and prevents severe damage to normal tissues, but selectively normalize and reset the immunity in tumor microenvironment.3 However, PD-L1/PD-1 is only responsible for a partial of dysfunctional immunity in human solid tumors.4 Therefore, identifying new normalizers will increase the spectrum of normalization cancer immunotherapy.